↓ Skip to main content

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Overview of attention for article published in New England Journal of Medicine, November 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Citations

dimensions_citation
630 Dimensions

Readers on

mendeley
490 Mendeley
citeulike
3 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Published in
New England Journal of Medicine, November 2016
DOI 10.1056/nejmoa1609214
Pubmed ID
Authors

Douglas B. Johnson, Justin M. Balko, Margaret L. Compton, Spyridon Chalkias, Joshua Gorham, Yaomin Xu, Mellissa Hicks, Igor Puzanov, Matthew R. Alexander, Tyler L. Bloomer, Jason R. Becker, David A. Slosky, Elizabeth J. Phillips, Mark A. Pilkinton, Laura Craig-Owens, Nina Kola, Gregory Plautz, Daniel S. Reshef, Jonathan S. Deutsch, Raquel P. Deering, Benjamin A. Olenchock, Andrew H. Lichtman, Dan M. Roden, Christine E. Seidman, Igor J. Koralnik, Jonathan G. Seidman, Robert D. Hoffman, Janis M. Taube, Luis A. Diaz, Robert A. Anders, Jeffrey A. Sosman, Javid J. Moslehi

Abstract

Immune checkpoint inhibitors have improved clinical outcomes associated with numerous cancers, but high-grade, immune-related adverse events can occur, particularly with combination immunotherapy. We report the cases of two patients with melanoma in whom fatal myocarditis developed after treatment with ipilimumab and nivolumab. In both patients, there was development of myositis with rhabdomyolysis, early progressive and refractory cardiac electrical instability, and myocarditis with a robust presence of T-cell and macrophage infiltrates. Selective clonal T-cell populations infiltrating the myocardium were identical to those present in tumors and skeletal muscle. Pharmacovigilance studies show that myocarditis occurred in 0.27% of patients treated with a combination of ipilimumab and nivolumab, which suggests that our patients were having a rare, potentially fatal, T-cell-driven drug reaction. (Funded by Vanderbilt-Ingram Cancer Center Ambassadors and others.).

Twitter Demographics

The data shown below were collected from the profiles of 381 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 490 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 <1%
Korea, Republic of 2 <1%
Sweden 1 <1%
Brazil 1 <1%
Canada 1 <1%
Japan 1 <1%
United Kingdom 1 <1%
Unknown 480 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 124 25%
Other 64 13%
Student > Ph. D. Student 49 10%
Student > Postgraduate 35 7%
Student > Master 32 7%
Other 120 24%
Unknown 66 13%
Readers by discipline Count As %
Medicine and Dentistry 244 50%
Biochemistry, Genetics and Molecular Biology 28 6%
Agricultural and Biological Sciences 27 6%
Immunology and Microbiology 27 6%
Pharmacology, Toxicology and Pharmaceutical Science 19 4%
Other 40 8%
Unknown 105 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 1256. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2020.
All research outputs
#3,408
of 15,099,074 outputs
Outputs from New England Journal of Medicine
#194
of 26,709 outputs
Outputs of similar age
#137
of 292,423 outputs
Outputs of similar age from New England Journal of Medicine
#12
of 281 outputs
Altmetric has tracked 15,099,074 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 26,709 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 76.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 292,423 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 281 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.